Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of ruxolitinib versus hydroxycarbamide in high-risk polycythaemia vera
2018-001908-11Phase 3Active
- Sponsor
- University of Birmingham
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ruxolitinib in polycythemia vera (PV), myeloproliferative disorder (MPD), sponsored by University of Birmingham. Started Jun 2022; status: active.
02
Drugs
03
Conditions
polycythemia vera (PV)myeloproliferative disorder (MPD)
Beyond the preview
Go deeper on 2018-001908-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001908-11.